Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
-0.09 (-0.24%)
After Hours: 37.10 -0.30 (-0.80%)
Nov 27, 3:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.04 - 38.19
52 week 11.33 - 41.97
Open 37.49
Vol / Avg. 1.01M/2.11M
Mkt cap 1.68B
P/E     -
Div/yield     -
EPS -4.83
Shares 45.27M
Beta 0.88
Inst. own 62%
Feb 24, 2016
Q4 2015 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 5, 2015
Q3 2015 Sarepta Therapeutics Inc Earnings Release
Nov 5, 2015
Q3 2015 Sarepta Therapeutics Inc Earnings Call - Webcast
Oct 1, 2015
Sarepta Therapeutics Inc Conference Call to Discuss Corporate Update and Report on Recent Data from Phase IIb Study - Webcast
Sep 17, 2015
Sarepta Therapeutics Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -1391.71%
Operating margin - -1371.21%
EBITD margin - -1313.34%
Return on average assets -100.05% -46.30%
Return on average equity -144.36% -54.88%
Employees 204 -
CDP Score - -


United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.

Officers and directors

Edward M. Kaye M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 54
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Director
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Age: 60
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters